Welcome to our dedicated page for Scisparc SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SciSparc Ltd. filings document foreign private issuer disclosures for a clinical-stage pharmaceutical company with ordinary shares listed on Nasdaq. The record includes Form 6-K reports and Form 20-F references covering NeuroThera Labs patent and clinical-regulatory updates, cannabinoid-based drug programs, the MUSE endoscopic-system IP portfolio, and hemp seed oil-based product operations.
The company’s SEC materials also describe capital-structure and financing matters, including convertible promissory notes, warrants, resale registration statements, Form F-3 and Form S-8 incorporation, shareholder meeting approvals, reverse-share-split mechanics, Nasdaq continued-listing compliance, governance matters and risk-related disclosure categories.
L.I.A. Pure Capital Ltd., an Israel-organized company, filed a Schedule 13G reporting a significant passive ownership position in SciSparc Ltd. ordinary shares. It reports beneficial ownership of 435,475 ordinary shares, with sole voting and sole dispositive power over all of these shares.
This holding represents 9.26% of SciSparc’s ordinary shares, based on 4,700,501 ordinary shares issued and outstanding as of the reporting date, a figure the issuer provided to the reporting person. The filing is made on a passive basis, with a certification that the securities were not acquired and are not held for the purpose of changing or influencing control of SciSparc.
SciSparc Ltd. is issuing 766,170 ordinary shares in a registered direct offering at $1.00 per share, for estimated net proceeds of about $0.7 million after offering expenses. Shares outstanding were 3,584,331 as of January 13, 2026 and are expected to be 4,350,501 after the sale.
The company plans to use the cash for working capital, including research and development, general corporate purposes, and potential strategic investments that may differ from its current business focus. Recent developments include a non-binding term sheet for its majority-owned subsidiary NeuroThera to acquire 55% of a quantum computing bio data analytics company, and an agreement for SciSparc to acquire the MUSE endoscopic IP portfolio from Xylo in exchange for shares (or pre-funded warrants) equal to 19.99% of its outstanding equity.
The document highlights significant risks, including potential dilution, an auditor going-concern paragraph, and a Nasdaq notice that the company fell below the $2.5 million stockholders’ equity requirement, creating a risk of delisting if compliance is not restored.
SciSparc Ltd. reported that it entered into a securities purchase agreement for a registered direct offering of 766,170 Ordinary Shares at $1.00 per share. This offering is expected to generate gross proceeds of approximately $766,170, which the company plans to use for working capital and general corporate purposes, as determined by its board of directors.
The shares are being issued under an existing shelf registration statement on Form F-3 via a prospectus supplement filed on January 13, 2026, and the closing of the offering is expected on or about January 14, 2026. An Israeli legal opinion confirms that the Ordinary Shares issued in the offering are validly issued, fully paid and non-assessable.
SciSparc Ltd. reported that on January 8, 2026 it signed an asset purchase agreement with Xylo Technologies Ltd. to acquire Xylo’s complete portfolio of patents, trademarks, know-how, brand names and related intellectual property rights, including unregistered rights. As consideration, SciSparc agreed to issue ordinary shares to Xylo so that, on the closing date, Xylo will hold Issued Shares representing 19.99% of SciSparc’s issued and outstanding share capital, and SciSparc may instead issue pre-funded warrants in whole or in part.
The transaction is expected to close on March 8, 2026, subject to customary closing conditions. SciSparc is obligated to ensure the Issued Shares represent 19.99% at closing and to file a registration statement with the SEC within 30 days after closing to register the resale of the Issued Shares. The company also highlighted a related press release describing the acquired portfolio as a “treasury of patents for the endoscope market – entering multi-billion dollar opportunity.”
SciSparc Ltd. reported that Nasdaq has notified the company it no longer meets the Nasdaq Capital Market’s minimum stockholders’ equity requirement of $2,500,000. In a prior Form 6-K, SciSparc disclosed stockholders’ equity of approximately $(81,000) as of June 30, 2025, triggering the non-compliance notice.
The company has 45 calendar days, until February 26, 2026, to submit a plan to regain compliance, and Nasdaq may grant up to 180 calendar days from the date of the letter to evidence compliance if the plan is accepted. The notice has no immediate effect on SciSparc’s Nasdaq listing, and its ordinary shares will continue to trade under the symbol SPRC during the grace period. SciSparc expects to show compliance as of December 31, 2025, supported by proceeds from the August 2025 conversion of $4.2 million principal plus accrued interest of debentures dated February 25, 2025 and a registered direct offering in November 2025.
SciSparc Ltd. (SPRC) reported that on November 26, 2025 it entered into a binding term sheet to acquire a complete portfolio of patents, trademarks, know-how, and related intellectual property, mainly associated with the MUSE™ system for innovative endoscopic systems and medical cameras, from Xylo Technologies Ltd.
As consideration for these intellectual property assets, SciSparc agreed to issue to Xylo ordinary shares that will represent, as of the closing date, 19.99% of SciSparc’s issued and outstanding share capital. SciSparc may choose, at its sole discretion, to issue pre-funded warrants to purchase ordinary shares instead of some or all of these shares. Closing is subject to customary conditions, including any required shareholder approval and the negotiation and signing of definitive agreements.
SciSparc also announced this planned acquisition in a press release titled “SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems,” and this report is incorporated by reference into several of the company’s existing Form F-3 and Form S-8 registration statements.
SciSparc Ltd. (SPRC) filed a Form 6-K noting that it has furnished a press release dated November 20, 2025. The release announces that Neurothera Labs submitted an Israeli patent application in collaboration with Clearmind Medicine for a novel non-hallucinogenic neuroplastogen treatment for depression. The filing also states that this Form 6-K is incorporated by reference into several of SciSparc’s existing shelf and employee equity registration statements, meaning the information becomes part of those previously filed offerings.
SciSparc Ltd. furnished a Form 6-K that provides its unaudited consolidated interim financial statements as of June 30, 2025, together with management’s discussion and analysis of financial condition and results of operations for the six months ended June 30, 2025.
The filing is incorporated by reference into SciSparc’s existing registration statements on Form F-3 and Form S-8, so these interim financials and related analysis become part of those offering documents from the submission date.
SciSparc Ltd. filed a prospectus supplement to update its F-4 prospectus with a Form 6-K detailing a new Framework Agreement with AutoMax Motors. The parties mutually terminated their prior merger agreement, rendering it null and void effective October 6, 2025.
The agreement sets specific loan repayments to SciSparc: AutoMax will repay a $4.25 million loan with 9% annual compound interest in a single lump-sum on January 1, 2028. A separate $2.0 million loan will be repaid in $60,000 monthly installments starting November 20, 2025, with 8% annual compound interest accruing to each payment date, plus $114,523 of accrued interest through November 20, 2025. The supplement incorporates the 6-K and attaches the Framework Agreement and related press release as exhibits.
SciSparc Ltd. (SPRC) reported it has closed the acquisition of a publicly traded company on the TSX Venture Exchange and transferred its advanced clinical‑stage pharmaceutical portfolio to that company. The announcement was furnished via a Form 6-K that also includes the related press release as an exhibit.
The Form 6-K is incorporated by reference into SciSparc’s effective registration statements on Forms F-3 and S-8, aligning the disclosure with its existing U.S. registration frameworks.